{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:54Z","timestamp":1787003814338,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early detection of drug-induced liver injury (DILI) during drug development is crucial for reducing drug attrition and ensuring the safety of patients. A versatile, biologically interpretable, and dose-dependent screening approach is therefore needed to inform early stop\/go decisions and therapeutic margins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We have developed AEGIS (Apoptotic Effector Genes In Safety), a preclinical DILI risk screening and prioritization tool that quantifies dose dependent perturbation of apoptosis-regulating transcription factors from transcriptomics data. We profiled transcriptomic responses after short exposures across primary human hepatocytes (PHH), HepG2\/C3A cells, RAW 264.7 cells, and an acute Balb\/c mouse study. From these profiles, AEGIS provides quantitative risk scores to rank and prioritize compounds and exposures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show that AEGIS distinguishes compounds with different degree of DILI concern, achieving 86% specificity, 75% sensitivity and 90% precision in PHHs. We demonstrate versatility in data type usage and clinical translation of AEGIS with accurate predictions across species, in vitro and in vivo models, and therapeutic modalities. In addition, we apply AEGIS in a precision medicine context during drug-development within the pharmaceutical industry and investigate the contribution of underlying liver disease on DILI severity. Our findings indicate that cells from patients with metabolic dysfunction-associated steatotic liver disease (MASLD) develop more severe DILI from treatment with troglitazone, aligning with preclinical observations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using AEGIS early in drug discovery exemplifies a more efficient approach to identify and mitigate potential safety concerns. This can reduce the need for animal testing, and accelerates drug discovery, ultimately providing the right medicines to patients more quickly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-025-01306-7","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T14:16:20Z","timestamp":1766585780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Apoptotic signatures allow early and rapid screening of drug-induced liver injury to accelerate drug discovery"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-7737","authenticated-orcid":false,"given":"John","family":"Hellgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-2552","authenticated-orcid":false,"given":"Bhavik","family":"Chouhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydar","family":"Uatay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2592-3448","authenticated-orcid":false,"given":"Ramy","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-2069","authenticated-orcid":false,"given":"Julia","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Pryde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0585-4756","authenticated-orcid":false,"given":"Patrik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sagemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-7475","authenticated-orcid":false,"given":"Bino","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-6298","authenticated-orcid":false,"given":"John","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan, P. et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17, 167\u2013181 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1306_CR2","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049\u20133062 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1306_CR3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","volume":"57","author":"E Kim","year":"2023","unstructured":"Kim, E., Yang, J., Park, S. & Shin, K. Factors affecting success of new drug clinical trials. Ther. Innov. Regul. Sci. 57, 737\u2013750 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"1306_CR4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","volume":"40","author":"S Harrer","year":"2019","unstructured":"Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence for clinical trial design. Trends Pharm. Sci. 40, 577\u2013591 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"1306_CR5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick, G. A. et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66, 1154\u20131164 (2017).","journal-title":"Gut"},{"key":"1306_CR6","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya, I. J., Heneghan, C. J. & Aronson, J. K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14, 10 (2016).","journal-title":"BMC Med."},{"key":"1306_CR7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-pharmtox-030220-015007","volume":"61","author":"T Yokoi","year":"2021","unstructured":"Yokoi, T. & Oda, S. Models of idiosyncratic drug-induced liver injury. Annu. Rev. Pharm. Toxicol. 61, 247\u2013268 (2021).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"1306_CR8","doi-asserted-by":"crossref","first-page":"116854","DOI":"10.1016\/j.taap.2024.116854","volume":"484","author":"MW Leach","year":"2024","unstructured":"Leach, M. W. et al. Translation of nonclinical to clinical safety findings for 27 biotherapeutics. Toxicol. Appl. Pharm. 484, 116854 (2024).","journal-title":"Toxicol. Appl. Pharm."},{"key":"1306_CR9","doi-asserted-by":"crossref","unstructured":"Meier, M. J. et al. Progress in toxicogenomics to protect human health. Nat. Rev. Genet. 26, 105\u2013122 (2024).","DOI":"10.1038\/s41576-024-00767-1"},{"key":"1306_CR10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e1417 (2017).","journal-title":"Cell"},{"key":"1306_CR11","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/HEP.0000000000000628","volume":"79","author":"Y Jin","year":"2024","unstructured":"Jin, Y. et al. An entropy weight method to integrate big omics and mechanistically evaluate DILI. Hepatology 79, 1264\u20131278 (2024).","journal-title":"Hepatology"},{"key":"1306_CR12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15932","volume":"8","author":"P Kohonen","year":"2017","unstructured":"Kohonen, P. et al. A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury. Nat. Commun. 8, 15932 (2017).","journal-title":"Nat. Commun."},{"key":"1306_CR13","doi-asserted-by":"crossref","first-page":"562677","DOI":"10.3389\/fbioe.2020.562677","volume":"8","author":"T Li","year":"2020","unstructured":"Li, T., Tong, W., Roberts, R., Liu, Z. & Thakkar, S. Deep learning on high-throughput transcriptomics to predict drug-induced liver injury. Front. Bioeng. Biotechnol. 8, 562677 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1306_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/toxsci\/kfaa094","volume":"177","author":"W Kang","year":"2020","unstructured":"Kang, W. et al. Development and application of a transcriptomic signature of bioactivation in an advanced in vitro liver model to reduce drug-induced liver injury risk early in the pharmaceutical pipeline. Toxicol. Sci. 177, 121\u2013139 (2020).","journal-title":"Toxicol. Sci."},{"key":"1306_CR15","doi-asserted-by":"crossref","unstructured":"Stolte, M. et al. Classification of hepatotoxicity of compounds based on cytotoxicity assays is improved by additional interpretable summaries of high-dimensional gene expression data. Comput. Toxicol. 28, 100288 (2023).","DOI":"10.1016\/j.comtox.2023.100288"},{"key":"1306_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cld.2019.09.006","volume":"24","author":"NA Hoppmann","year":"2020","unstructured":"Hoppmann, N. A., Gray, M. E. & McGuire, B. M. Drug-induced liver injury in the setting of chronic liver disease. Clin. Liver Dis. 24, 89\u2013106 (2020).","journal-title":"Clin. Liver Dis."},{"key":"1306_CR17","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023).","journal-title":"Hepatology"},{"key":"1306_CR18","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter, T. G. & Rinella, M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158, 1851\u20131864 (2020).","journal-title":"Gastroenterology"},{"key":"1306_CR19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","volume":"107","author":"A Vildhede","year":"2020","unstructured":"Vildhede, A., Kimoto, E., Pelis, R. M., Rodrigues, A. D. & Varma, M. V. S. Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease. Clin. Pharm. Ther. 107, 1128\u20131137 (2020).","journal-title":"Clin. Pharm. Ther."},{"key":"1306_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.apsb.2022.08.018","volume":"13","author":"S Marie","year":"2023","unstructured":"Marie, S. et al. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharm. Sin. B 13, 1\u201328 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"1306_CR21","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/hep.31999","volume":"74","author":"I Rusyn","year":"2021","unstructured":"Rusyn, I. et al. Key Characteristics of human hepatotoxicants as a basis for identification and characterization of the causes of liver toxicity. Hepatology 74, 3486\u20133496 (2021).","journal-title":"Hepatology"},{"key":"1306_CR22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.117.246751","volume":"365","author":"D Le Guillou","year":"2018","unstructured":"Le Guillou, D. et al. Drug-induced alterations of mitochondrial DNA homeostasis in steatotic and nonsteatotic HepaRG cells. J. Pharm. Exp. Ther. 365, 711\u2013726 (2018).","journal-title":"J. Pharm. Exp. Ther."},{"key":"1306_CR23","doi-asserted-by":"crossref","first-page":"105728","DOI":"10.1016\/j.tiv.2023.105728","volume":"94","author":"J Bronsard","year":"2024","unstructured":"Bronsard, J. et al. 3D multi-cell-type liver organoids: a new model of non-alcoholic fatty liver disease for drug safety assessments. Toxicol. Vitr. 94, 105728 (2024).","journal-title":"Toxicol. Vitr."},{"key":"1306_CR24","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2131\/jts.43.339","volume":"43","author":"M Segawa","year":"2018","unstructured":"Segawa, M., Sekine, S., Sato, T. & Ito, K. Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat. J. Toxicol. Sci. 43, 339\u2013351 (2018).","journal-title":"J. Toxicol. Sci."},{"key":"1306_CR25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00204-019-02427-4","volume":"93","author":"AJ Foster","year":"2019","unstructured":"Foster, A. J. et al. Integrated in vitro models for hepatic safety and metabolism: evaluation of a human liver-chip and liver spheroid. Arch. Toxicol. 93, 1021\u20131037 (2019).","journal-title":"Arch. Toxicol."},{"key":"1306_CR26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen, M. et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov. Today 21, 648\u2013653 (2016).","journal-title":"Drug Discov. Today"},{"key":"1306_CR27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.28678","volume":"64","author":"M Chen","year":"2016","unstructured":"Chen, M., Borlak, J. & Tong, W. A model to predict severity of drug-induced liver injury in humans. Hepatology 64, 931\u2013940 (2016).","journal-title":"Hepatology"},{"key":"1306_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acs.chemrestox.9b00264","volume":"33","author":"DP Williams","year":"2020","unstructured":"Williams, D. P., Lazic, S. E., Foster, A. J., Semenova, E. & Morgan, P. Predicting drug-induced liver injury with Bayesian machine learning. Chem. Res. Toxicol. 33, 239\u2013248 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"1306_CR29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tiv.2013.10.015","volume":"28","author":"H Garside","year":"2014","unstructured":"Garside, H. et al. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Toxicol. Vitr. 28, 171\u2013181 (2014).","journal-title":"Toxicol. Vitr."},{"key":"1306_CR30","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00204-017-2002-1","volume":"91","author":"WR Proctor","year":"2017","unstructured":"Proctor, W. R. et al. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch. Toxicol. 91, 2849\u20132863 (2017).","journal-title":"Arch. Toxicol."},{"key":"1306_CR31","volume":"9","author":"C Ye","year":"2018","unstructured":"Ye, C. et al. DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery. Nat. Commun. 9, 4307 (2018).","journal-title":"Nat. Commun."},{"key":"1306_CR32","doi-asserted-by":"crossref","first-page":"D921","DOI":"10.1093\/nar\/gku955","volume":"43","author":"Y Igarashi","year":"2015","unstructured":"Igarashi, Y. et al. Open TG-GATEs: a large-scale toxicogenomics database. Nucleic Acids Res. 43, D921\u2013D927 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1306_CR33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/mnfr.200900169","volume":"54","author":"T Uehara","year":"2010","unstructured":"Uehara, T. et al. The Japanese toxicogenomics project: application of toxicogenomics. Mol. Nutr. Food Res. 54, 218\u2013227 (2010).","journal-title":"Mol. Nutr. Food Res."},{"key":"1306_CR34","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"1306_CR35","unstructured":"Korotkevich, G. et al Fast gene set enrichment analysis. bioRxiv, (2021)."},{"key":"1306_CR36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1306_CR37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1101\/gr.240663.118","volume":"29","author":"L Garcia-Alonso","year":"2019","unstructured":"Garcia-Alonso, L., Holland, C. H., Ibrahim, M. M., Turei, D. & Saez-Rodriguez, J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 29, 1363\u20131375 (2019).","journal-title":"Genome Res."},{"key":"1306_CR38","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1093\/bioinformatics\/btq401","volume":"26","author":"D Wu","year":"2010","unstructured":"Wu, D. et al. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 26, 2176\u20132182 (2010).","journal-title":"Bioinformatics"},{"key":"1306_CR39","doi-asserted-by":"crossref","first-page":"e8636","DOI":"10.15252\/msb.20188636","volume":"15","author":"K Shimada","year":"2019","unstructured":"Shimada, K. & Mitchison, T. J. Unsupervised identification of disease states from high-dimensional physiological and histopathological profiles. Mol. Syst. Biol. 15, e8636 (2019).","journal-title":"Mol. Syst. Biol."},{"key":"1306_CR40","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s11095-014-1591-0","volume":"32","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. MITOsym(R): a mechanistic, mathematical model of hepatocellular respiration and bioenergetics. Pharm. Res. 32, 1975\u20131992 (2015).","journal-title":"Pharm. Res."},{"key":"1306_CR41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Prim. 5, 58 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1306_CR42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","volume":"20","author":"ST Crooke","year":"2021","unstructured":"Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X. H. Antisense technology: an overview and prospectus. Nat. Rev. Drug Discov. 20, 427\u2013453 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1306_CR43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani, F. et al. Adverse drug reactions and toxicity of the food and drug administration-approved antisense oligonucleotide drugs. Drug Metab. Dispos. 50, 879\u2013887 (2022).","journal-title":"Drug Metab. Dispos."},{"key":"1306_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2022.0061","volume":"33","author":"A Goyenvalle","year":"2023","unstructured":"Goyenvalle, A. et al. Considerations in the preclinical assessment of the safety of antisense oligonucleotides. Nucleic Acid Ther. 33, 1\u201316 (2023).","journal-title":"Nucleic Acid Ther."},{"key":"1306_CR45","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1111\/bph.13548","volume":"173","author":"K Ploj","year":"2016","unstructured":"Ploj, K. et al. Effects of a novel potent melanin-concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs. Br. J. Pharm. 173, 2739\u20132751 (2016).","journal-title":"Br. J. Pharm."},{"key":"1306_CR46","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cld.2019.09.003","volume":"24","author":"PB Watkins","year":"2020","unstructured":"Watkins, P. B. Quantitative systems toxicology approaches to understand and predict drug-induced liver injury. Clin. Liver Dis. 24, 49\u201360 (2020).","journal-title":"Clin. Liver Dis."},{"key":"1306_CR47","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/liv.15262","volume":"42","author":"X Li","year":"2022","unstructured":"Li, X., Tang, J. & Mao, Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 42, 1999\u20132014 (2022).","journal-title":"Liver Int."},{"key":"1306_CR48","first-page":"212","volume":"3","author":"J Massart","year":"2017","unstructured":"Massart, J., Begriche, K., Moreau, C. & Fromenty, B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J. Clin. Transl. Res. 3, 212\u2013232 (2017).","journal-title":"J. Clin. Transl. Res."},{"key":"1306_CR49","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/apt.14952","volume":"48","author":"F Bessone","year":"2018","unstructured":"Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V. & Roma, M. G. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view. Aliment Pharm. Ther. 48, 892\u2013913 (2018).","journal-title":"Aliment Pharm. Ther."},{"key":"1306_CR50","volume":"9","author":"SA Hoang","year":"2019","unstructured":"Hoang, S. A. et al. Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci. Rep. 9, 12541 (2019).","journal-title":"Sci. Rep."},{"key":"1306_CR51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96966-5","volume":"11","author":"L Pantano","year":"2021","unstructured":"Pantano, L. et al. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci. Rep. 11, 18045 (2021).","journal-title":"Sci. Rep."},{"key":"1306_CR52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","volume":"85","author":"J Allard","year":"2019","unstructured":"Allard, J., Le Guillou, D., Begriche, K. & Fromenty, B. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv. Pharm. 85, 75\u2013107 (2019).","journal-title":"Adv. Pharm."},{"key":"1306_CR53","doi-asserted-by":"crossref","unstructured":"Wang S. & Friedman, S. L. Found in translation\u2014Fibrosis in metabolic dysfunction\u2013associated steatohepatitis (MASH). Sci. Transl. Med. 15, eadi0759 (2023).","DOI":"10.1126\/scitranslmed.adi0759"},{"key":"1306_CR54","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.tem.2022.07.001","volume":"33","author":"JA Hoogerland","year":"2022","unstructured":"Hoogerland, J. A., Staels, B. & Dombrowicz, D. Immune\u2013metabolic interactions in homeostasis and the progression to NASH. Trends Endocrinol. Metab. 33, 690\u2013709 (2022).","journal-title":"Trends Endocrinol. Metab."},{"key":"1306_CR55","doi-asserted-by":"crossref","first-page":"155811","DOI":"10.1016\/j.metabol.2024.155811","volume":"154","author":"Z Dashti","year":"2024","unstructured":"Dashti, Z. et al. Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth. Metabolism 154, 155811 (2024).","journal-title":"Metabolism"},{"key":"1306_CR56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.livres.2020.02.004","volume":"4","author":"H Chen","year":"2020","unstructured":"Chen, H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Res. 4, 15\u201322 (2020).","journal-title":"Liver Res."},{"key":"1306_CR57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2016.05.051","volume":"151","author":"A Teufel","year":"2016","unstructured":"Teufel, A. et al. Comparison of gene expression patterns between mouse models of nonalcoholic fatty liver disease and liver tissues from patients. Gastroenterology 151, 513\u2013525.e510 (2016).","journal-title":"Gastroenterology"},{"key":"1306_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06512-0","volume":"12","author":"Y Hasin-Brumshtein","year":"2022","unstructured":"Hasin-Brumshtein, Y., Sakaram, S., Khatri, P., He, Y. D. & Sweeney, T. E. A robust gene expression signature for NASH in liver expression data. Sci. Rep. 12, 2571 (2022).","journal-title":"Sci. Rep."},{"key":"1306_CR59","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/liv.12514","volume":"34","author":"A Michaut","year":"2014","unstructured":"Michaut, A., Moreau, C., Robin, M. A. & Fromenty, B. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease. Liver Int. 34, e171\u2013e179 (2014).","journal-title":"Liver Int."},{"key":"1306_CR60","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner, D. E. et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59, 661\u2013670 (2014).","journal-title":"Hepatology"},{"key":"1306_CR61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfy058","volume":"163","author":"SU Vorrink","year":"2018","unstructured":"Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M. & Lauschke, V. M. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. Toxicol. Sci. 163, 655\u2013665 (2018).","journal-title":"Toxicol. Sci."},{"key":"1306_CR62","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1002\/bit.27931","volume":"118","author":"RR Xiao","year":"2021","unstructured":"Xiao, R. R. et al. An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. Biotechnol. Bioeng. 118, 4687\u20134698 (2021).","journal-title":"Biotechnol. Bioeng."},{"key":"1306_CR63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","volume":"2","author":"L Ewart","year":"2022","unstructured":"Ewart, L. et al. Performance assessment and economic analysis of a human liver-chip for predictive toxicology. Commun. Med. 2, 154 (2022).","journal-title":"Commun. Med."},{"key":"1306_CR64","first-page":"273","volume":"39","author":"D Ramsden","year":"2022","unstructured":"Ramsden, D. et al. Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics. ALTEX 39, 273\u2013296 (2022).","journal-title":"ALTEX"},{"key":"1306_CR65","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1872-034X.2007.00072.x","volume":"37","author":"G Tarantino","year":"2007","unstructured":"Tarantino, G. et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. 37, 410\u2013415 (2007).","journal-title":"Hepatol. Res."},{"key":"1306_CR66","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.cgh.2018.12.013","volume":"17","author":"C Lammert","year":"2019","unstructured":"Lammert, C., Imler, T., Teal, E. & Chalasani, N. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin. Gastroenterol. Hepatol. 17, 2814\u20132815 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1306_CR67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cgh.2021.06.023","volume":"20","author":"S Hwang","year":"2022","unstructured":"Hwang, S., Won, S. & Lee, S. Nonalcoholic fatty liver disease for the incidence of drug-induced liver injury. Clin. Gastroenterol. Hepatol. 20, 964\u2013965 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1306_CR68","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury:the DILIN prospective study. Gastroenterology 148, 1340\u20131352.e1347 (2015).","journal-title":"Gastroenterology"},{"key":"1306_CR69","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/hep.31857","volume":"74","author":"S McCarron","year":"2021","unstructured":"McCarron, S. et al. Functional characterization of organoids derived from irreversibly damaged liver of patients with NASH. Hepatology 74, 1825\u20131844 (2021).","journal-title":"Hepatology"},{"key":"1306_CR70","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41587-023-01680-4","volume":"41","author":"D Hendriks","year":"2023","unstructured":"Hendriks, D. et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis. Nat. Biotechnol. 41, 1567\u20131581 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1306_CR71","doi-asserted-by":"crossref","unstructured":"Danan, G. & Teschke R. RUCAM in drug and herb induced liver injury: the update. Int. J. Mol. Sci. 17, 14 (2015).","DOI":"10.3390\/ijms17010014"},{"key":"1306_CR72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acs.chemrestox.9b00275","volume":"33","author":"SE Ali","year":"2020","unstructured":"Ali, S. E., Waddington, J. C., Park, B. K. & Meng, X. Definition of the chemical and immunological signals involved in drug-induced liver injury. Chem. Res. Toxicol. 33, 61\u201376 (2020).","journal-title":"Chem. Res. Toxicol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01306-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:17:11Z","timestamp":1769098631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01306-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01306-7","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T., B.J. and J.G. are currently employees at GSK, Boehringer Ingelheim and Tagomics, respectively. All authors are\/have been employees of AstraZeneca and have stock ownership and\/or stock options or interest in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}